Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman Wolmark

Showing results (61-70 of 232) with videos related to

Pageof 24
Sort By:
Cancer|September 24, 2020
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine reportMonica M Bertagnolli, Charles D Blanke, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Breast Cancer Research and Treatment|January 12, 2011
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Gong Tang, Steven Shak, Soonmyung Paik, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 10, 2012
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsReena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approachesStephanie R Land, Marcie W Ritter, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatinGreg Yothers, Michael J O'Connell, Mark Lee, et al.
Breast Cancer Research and Treatment|July 2, 2015
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9Jame Abraham, André Robidoux, Antoinette R Tan, et al.
Clinical Breast Cancer|January 24, 2007
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancerEleftherios P Mamounas, Barry Lembersky, Jong-Hyeon Jeong, et al.
American Journal of Obstetrics and Gynecology|August 30, 2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)Carolyn D Runowicz, Joseph P Costantino, D Lawrence Wickerham, et al.
Pageof 24

Showing results (61-70 of 232) with videos related to

Sort By:
Pageof 24
Cancer|September 24, 2020
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine reportMonica M Bertagnolli, Charles D Blanke, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Breast Cancer Research and Treatment|January 12, 2011
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Gong Tang, Steven Shak, Soonmyung Paik, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 10, 2012
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsReena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approachesStephanie R Land, Marcie W Ritter, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatinGreg Yothers, Michael J O'Connell, Mark Lee, et al.
Breast Cancer Research and Treatment|July 2, 2015
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9Jame Abraham, André Robidoux, Antoinette R Tan, et al.
Clinical Breast Cancer|January 24, 2007
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancerEleftherios P Mamounas, Barry Lembersky, Jong-Hyeon Jeong, et al.
American Journal of Obstetrics and Gynecology|August 30, 2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)Carolyn D Runowicz, Joseph P Costantino, D Lawrence Wickerham, et al.
Pageof 24